AGENDA

Uniform Formulary Beneficiary Advisory Panel (BAP)
24 June 2020 @ 1 PM Eastern Daylight Time (Note new meeting time)

Virtual Meeting

- Administrative Meeting starts at 12:30 PM Eastern Daylight Time
- Sign-In
- Roll Call
- Welcome and Opening Remarks
- Newly Approved Drugs per 32 CFR 199.21(g)(5)

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) for the newly approved drugs.

The P&T Committee made recommendations for the following drugs/drug classes during the May 2020 meeting:

- **antihemophilic factor (recombinant) glycoPEGylated-exei (Esperoct)** — Antihemophilic Factor; new recombinant pegylated formulation of factor VIII
- **avapritinib (Ayvakit)** — Oncological agent for gastrointestinal stromal tumors (GIST)
- **cenobamate (Xcopri)** — Anticonvulsants-Antimania Agents; for partial-onset seizures
- **diazepam nasal spray (Valtoco)** — Anticonvulsants-Antimania Agents; new nasal spray formulation of diazepam for seizures
- **metformin ER suspension (Riomet ER)** — Diabetes Non-Insulin Drugs, Biguanides; new extended-release oral suspension formulation of metformin
- **peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia)** — Miscellaneous Immunologic Agent for peanut allergy
- **rimegepant orally disintegrating tablet (Nurtec ODT)** — Migraine agent for acute treatment of migraine
- **tazemetostat (Tazverik)** — Oncological agent for epithelioid sarcoma
- **bempedoic acid (Nexletol)** — Antilipidemic I (LIP-1) approved as an adjunct to a statin to reduce low density lipoprotein (LDL) cholesterol
• cetirizine 0.24% ophthalmic solution (Zerviate) — Ophthalmic Allergy Drugs; new ophthalmic formulation of cetirizine

• lasmiditan (Reyvow) — Migraine Agent for acute treatment of migraine

• lumateperone (Caplyta) — Atypical Antipsychotic for schizophrenia

• teriparatide (Bonsity) — Osteoporosis Agents: Parathyroid Hormone, a biosimilar of Forteo for osteoporosis

• ubrogepant (Ubrelvy) — Migraine Agent for acute treatment of migraine

➢ Panel Discussions

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.